Actively Recruiting
Comparing Starting Doses of Follicle-Stimulating Hormone 225 IU vs 300 IU During Progestin-Primed Ovarian Stimulation For Women with Good Prognosis Undergoing IVF
Led by Vietnam Military Medical University · Updated on 2026-10-20
380
Participants Needed
1
Research Sites
61 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are comparing two starting doses of follicle-stimulating hormone FSH, 225 IU and 300 IU, during progestin-primed ovarian stimulation PPOS for women with a good reproductive prognosis undergoing in vitro fertilization IVF. The study aims to find out if the initial FSH dose impacts oocyte and embryo development, focusing on blastocyst formation as the main outcome. This trial is randomized and controlled, designed to clarify the optimal FSH dose in this specific IVF protocol. Participants are randomly assigned to receive either 225 IU or 300 IU of FSH daily through subcutaneous injections during ovarian stimulation. The assigned dose remains constant throughout the stimulation period. The study includes monitoring through the first frozen embryo transfer cycle to assess outcomes based on embryos created during the study cycle. During the trial, participants will undergo assessments related to oocyte characteristics, fertilization rates, embryo development, and blastocyst quality. Researchers will collect data at specific times, such as before and after intracytoplasmic sperm injection ICSI and after embryo culture stages. Pregnancy outcomes will also be evaluated following frozen embryo transfer. The study duration extends until the study completion date, ensuring thorough monitoring of treatment effects.
CONDITIONS
Brief Title
225 IU Versus 300 IU Starting FSH Dose in PPOS for Good-Prognosis Women
Research Team
T
Truc Nhu Thanh Vo, PhD Student
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here